DLGAP2 and Alzheimer disease: We observed a similar pattern in CFM outcomes; two‐way repeated‐measures ANOVA detected a significant decrease in DLGAP2–overexpressing mice compared to control injections (F[1, 57] = 6.63, p < 0.05) and a decrease from 6‐ to 14‐month age points (F[1, 57] = 10.12, p < 0.01), alongside significant interactions between AD status × age (F[1, 57] = 23.78, p < 0.001) (Figure S5), and AAV construct × age (F[1, 57] = 4.84, p < 0.05).